Mineralocorticoid Receptor Antagonists May Lower Death Risk in Dialysis
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Older adults and individuals with diabetes did not experience a faster decline in SARS-CoV-2 antibody titers, investigators found.
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Overall control of hyperparathyroidism and hyperphosphatemia appeared to be associated with a reduction in left ventricular mass, however.
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.